Senti Biosciences Holdings Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
SNTI
- Investments
-
2
- Share Price
-
$0.14
- (As of Friday Closing)
Senti Biosciences Holdings General Information
Description
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Contact Information
Website
www.sentibio.comCorporate Office
- 2 Corporate Drive
- First Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 2 Corporate Drive
- First Floor
- South San Francisco, CA 94080
- United States
Senti Biosciences Holdings Timeline
Senti Biosciences Holdings Stock Performance
As of 13-Nov-2026, Senti Biosciences Holdings’s stock price is $0.14. Its current market cap is $5.38M with 38.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.14 | $0.15 | $0.14 - $2.88 | $5.38M | 38.5M | 3.51M | -$1.77 |
Senti Biosciences Holdings Financials Summary
As of 30-Jun-2026, Senti Biosciences Holdings has a trailing 12-month revenue of $55K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 44,465 | 45,220 | 40,336 | 27,283 |
| Revenue | 55 | 22 | 0 | 1,978 |
| EBITDA | (46,831) | (58,728) | (49,900) | (80,841) |
| Net Income | (49,564) | (61,438) | (52,790) | (71,058) |
| Total Assets | 33,105 | 51,223 | 97,841 | 119,484 |
| Total Debt | 20,226 | 28,891 | 33,538 | 37,666 |
Senti Biosciences Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Senti Biosciences Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Senti Biosciences Holdings Comparisons
Industry
Financing
Details
Senti Biosciences Holdings Competitors (44)
One of Senti Biosciences Holdings’s 44 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| GenSight Biologics | Formerly VC-backed | Paris, France |
Senti Biosciences Holdings Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Senti Biosciences Holdings Patents
Senti Biosciences Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136971-A1 | Engineered cell therapies, methods of administration thereof and methods of monitoring thereof | Pending | 20-Dec-2024 | ||
| WO-2026085275-A1 | Bivalent chimeric receptors or chimeric receptor systems and methods of use thereof | Pending | 16-Oct-2024 | ||
| WO-2026030634-A2 | Sustained transgene expression of imid-responsive peptide-suicide protein fusion polypeptides and uses thereof | Pending | 01-Aug-2024 | ||
| WO-2026030634-A3 | Sustained transgene expression of imid-responsive peptide-suicide protein fusion polypeptides and uses thereof | Pending | 01-Aug-2024 | ||
| WO-2026006316-A2 | Phenotype locking and switching mechanisms in stem cells and stem-cell derived immune cells | Pending | 25-Jun-2024 | C12N5/0606 |
Senti Biosciences Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Senti Biosciences Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Senti Biosciences Holdings Investments & Acquisitions (2)
Senti Biosciences Holdings’s most recent deal was a Merger/Acquisition with Dynamics Special Purpose for . The deal was made on 08-Jun-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dynamics Special Purpose | 08-Jun-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Lexent Bio | 01-Nov-2017 | Early Stage VC | Decision/Risk Analysis |
Senti Biosciences Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Senti Biosciences Holdings Exits (1)
Senti Biosciences Holdings’s most recent exit was on 01-Nov-2017 from Lexent Bio. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Lexent Bio | 01-Nov-2017 | Completed |
|
Senti Biosciences Holdings FAQs
-
When was Senti Biosciences Holdings founded?
Senti Biosciences Holdings was founded in 2016.
-
Where is Senti Biosciences Holdings headquartered?
Senti Biosciences Holdings is headquartered in South San Francisco, CA.
-
What is the size of Senti Biosciences Holdings?
Senti Biosciences Holdings has 39 total employees.
-
What industry is Senti Biosciences Holdings in?
Senti Biosciences Holdings’s primary industry is Drug Discovery.
-
Is Senti Biosciences Holdings a private or public company?
Senti Biosciences Holdings is a Public company.
-
What is Senti Biosciences Holdings’s stock symbol?
The ticker symbol for Senti Biosciences Holdings is SNTI.
-
What is the current stock price of Senti Biosciences Holdings?
As of 13-Nov-2026 the stock price of Senti Biosciences Holdings is $0.14.
-
What is the current market cap of Senti Biosciences Holdings?
The current market capitalization of Senti Biosciences Holdings is $5.38M.
-
What is Senti Biosciences Holdings’s current revenue?
The trailing twelve month revenue for Senti Biosciences Holdings is $55K.
-
Who are Senti Biosciences Holdings’s competitors?
Kite Pharma, Inovio Pharmaceuticals, Oncorus, Orchard Therapeutics, and GenSight Biologics are some of the 44 competitors of Senti Biosciences Holdings.
-
What is Senti Biosciences Holdings’s annual earnings per share (EPS)?
Senti Biosciences Holdings’s EPS for 12 months was -$1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
